In a June 10 story about diabetes treatment research, The Associated Press reported erroneously that LY2605541 is a short-acting insulin. It is a long-acting insulin.
Also, Johnson & Johnson applied for U.S. approval to sell its experimental diabetes pill canagliflozin on May 31, not May 29.
Tonight's New Hampshire GOP Debate Preview | RedState
Dead broke candidate thinks $150K donation is “not very much money”
America is a Nation Headed For a Fall
'Letter of consent before every snap': #NFLonVox takes Vox's football explainer to the house
Why Muslim Rapists Prefer Blondes: A History | Human Events
Mike Shedlock - Recession has Arrived; Factory Orders Decline 2.9%, Inventories Rise
Ruling In "Assault Weapons" Case Could Gut Gun Control Nationwide